Table 3.
Pathologic complete response in four Alliance clinical trials according to race, ethnicity and BMI (N=1672)
| Na | %pCR | OR (95% CI)b | |
|---|---|---|---|
| Race | |||
| White | 1381 | 550 (39.8) | 1.0 (reference) |
| Black | 245 | 99 (40.4) | 1.18 (0.85, 1.62) |
| Ethnicity | |||
| Non-Hispanic | 1441 | 570 (39.6) | 1.0 (reference) |
| Hispanic | 194 | 90 (46.4) | 1.22 (0.86, 1.72) |
| BMI (kg/m2) | |||
| <20 | 64 | 33 (51.6) | 1.60 (0.89, 2.86) |
| 20–24 | 454 | 198 (43.6) | 1.0 (reference) |
| 25–29 | 510 | 198 (38.8) | 0.86 (0.64, 1.16) |
| ≥30 | 722 | 277 (38.4) | 0.82 (0.62, 1.08) |
| p-trend c | 0.094 | ||
| Subtype | |||
| ER+/HER2− | 416 | 66 (15.9) | 1.0 (reference) |
| ER+/HER2+ | 399 | 152 (38.1) | 2.16 (1.32, 3.51) |
| ER−/HER2+ | 311 | 195 (62.7) | 5.48 (3.40, 8.85) |
| Triple Negative | 611 | 285 (46.6) | 2.56 (1.75, 3.75) |
a
125 women excluded due to missing values of variables;
b
mutually adjusted for all variables in table plus trial arm, tumor grade, lymph node status, tumor size, and subtype;
c
p-trend is from a test of linear trend of an ordinal variable defined by the median of each category.